PLEOPHARMA, INC. — SEC Form D Filing
PLEOPHARMA, INC. filed an SEC Form D on August 10, 2026, reporting $5.50M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 10, 2026
- Amount reported
- $5.50M
- Round stage
- Series A
- Industry
- Pharmaceuticals
- Website
- https://www.pleopharma.com/
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Millions of people suffer needlessly due to the lack of FDA-approved solutions for unmet needs in the CNS and substance abuse space. Specifically, there is no effective treatment for the severe distress and discomfort of cannabis withdrawal syndrome (CWS), which impedes individuals trying to discontinue cannabis use.
Solution
PleoPharma is developing therapies, with their lead program already having successfully completed Phase 2, to address these unmet and growing needs. The company aims to find a safe and effective treatment for Cannabis Use Disorder (CUD) and Cannabis Withdrawal Syndrome (CWS).
Why now
The widespread legalization and commercialization of cannabis have led to a significant increase in cannabis use disorder diagnoses, creating an urgent demand for targeted medical treatments.
Verdict
Investors backed this Series A because the company presented a de-risked Phase 2 asset in a clearly defined, underserved medical niche, not because of a broad play in CNS. The implicit bet was on a clear regulatory pathway to approval for CWS, driven by the emergent need from cannabis legalization. Upside was constrained by the singular focus on cannabis withdrawal, limiting its immediate market size compared to broader addiction therapeutics.
Source: SEC EDGAR Form D filing